Technical Analysis for ASMB - Assembly Biosciences, Inc.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| See historical ASMB trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Mar 20 | MACD Bearish Signal Line Cross | Bearish | 0.00% |
| Mar 19 | Narrow Range Bar | Range Contraction | -5.78% |
| Mar 19 | NR7 | Range Contraction | -5.78% |
| Mar 19 | Multiple of Ten Bearish | Other | -5.78% |
| Mar 19 | Inside Day | Range Contraction | -5.78% |
| Mar 18 | MACD Bullish Signal Line Cross | Bullish | -4.63% |
| Mar 18 | Volume Surge | Other | -4.63% |
| Mar 18 | Multiple of Ten Bearish | Other | -4.63% |
| Mar 15 | 20 DMA Resistance | Bearish | -7.41% |
| Mar 15 | Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -7.41% |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2019-03-14
- Sector: Healthcare
- Industry: Specialty & Advanced Pharmaceuticals
Assembly Biosciences, Inc. provides development and commercialization of gastrointestinal products in the United States. The company is developing two late-stage development product candidates, including VEN 307, a diltiazem cream for the relief of pain associated with anal fissures; and VEN 308, a phenylephrine gel for the treatment of fecal incontinence associated with ileal pouch anal anastomosis. It is also involved in the development of VEN 310 as a colonic delivery mechanism, which is a PH sensitive system to deliver bacteria, complex proteins, viral antigens, small molecules, and other treatments. The company was formerly known as Ventrus Biosciences Inc. and changed its name to Assembly Biosciences, Inc. in July, 2014. Assembly Biosciences, Inc. was founded in 2005 and is based in New York, New York.
Medicine Medical Specialties Gastroenterology Digestive System Digestive System Surgery Large Intestine Fecal Incontinence Gastrointestinal Products
Medicine Medical Specialties Gastroenterology Digestive System Digestive System Surgery Large Intestine Fecal Incontinence Gastrointestinal Products
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more ASMB news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 63.155 |
| 52 Week Low | 17.705 |
| Average Volume | 242,976 |
| 200-Day Moving Average | 30.069 |
| 50-Day Moving Average | 21.218 |
| 20-Day Moving Average | 20.2525 |
| 10-Day Moving Average | 19.436 |
| Average True Range | 1.2143 |
| ADX | 15.44 |
| +DI | 18.9356 |
| -DI | 25.6769 |
| Chandelier Exit (Long, 3 ATRs ) | 19.8171 |
| Chandelier Exit (Short, 3 ATRs ) | 21.3479 |
| Upper Bollinger Band | 22.5684 |
| Lower Bollinger Band | 17.9366 |
| Percent B (%b) | 0.17 |
| BandWidth | 22.870263 |
| MACD Line | -0.6371 |
| MACD Signal Line | -0.6171 |
| MACD Histogram | -0.02 |
| Fundamentals | Value |
|---|---|
| Market Cap | 325.22 Million |
| Num Shares | 17.4 Million |
| EPS | -2.93 |
| Price-to-Earnings (P/E) Ratio | -6.39 |
| Price-to-Sales | 176.68 |
| Price-to-Book | 9.51 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 20.52 | ||||
| Resistance 3 (R3) | 20.69 | 20.26 | 20.22 | ||
| Resistance 2 (R2) | 20.26 | 19.81 | 20.18 | 20.12 | |
| Resistance 1 (R1) | 19.50 | 19.53 | 19.29 | 19.33 | 20.02 |
| Pivot Point | 19.07 | 19.07 | 18.97 | 18.99 | 19.07 |
| Support 1 (S1) | 18.31 | 18.62 | 18.10 | 18.14 | 17.44 |
| Support 2 (S2) | 17.88 | 18.34 | 17.80 | 17.34 | |
| Support 3 (S3) | 17.12 | 17.88 | 17.24 | ||
| Support 4 (S4) | 16.95 |
